Forigerimod
Also known as: IPP-201101, Lupuzor, P140, P140 peptide
Source Forigerimod at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Forigerimod (P140 peptide, IPP-201101) is an investigational phosphopeptide being developed primarily for the treatment of systemic lupus erythematosus (SLE). It selectively targets overactivated immune cells without broadly suppressing the immune system. Phase II and Phase III clinical trials have been conducted, showing signals of efficacy in SLE patients, particularly in reducing disease activity scores.
Mechanism of Action
Forigerimod (P140 peptide) is a phosphopeptide derived from the U1-70K snRNP protein. It binds to HSC70 (heat shock cognate protein 70) and inhibits aberrant MHC class II-mediated autophagy-driven antigen presentation, thereby downregulating overactivated T and B lymphocyte responses characteristic of systemic lupus erythematosus (SLE). It modulates innate immune signaling by interfering with TLR7/TLR9 pathways.
Routes of Administration
Goals & Uses
- Immune modulation without broad immunosuppressionTargeted ImmunotherapyModerate
- Reduction of anti-dsDNA antibodiesBiomarker ModulationModerate
- Steroid-sparing effectCorticosteroid ReductionLow
- Reduction of SLE disease activityAutoimmune/InflammatoryModerate
Contraindications
- Hypersensitivity to forigerimod or excipientsAllergy / HypersensitivityHigh
- PregnancyPopulationModeratePotential fetal risk or insufficient safety data
- Active severe infectionInfectiousHigh
Adverse Effects
- Hypersensitivity reactionsImmunologicRare
- Injection site reactionsLocalCommon
- HeadacheNeurologicUncommonPain in the head or upper neck
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
Drug Interactions
- HydroxychloroquineLow
- CorticosteroidsLow
- Mycophenolate mofetilLow
Population Constraints
- Pediatric patientsAgeRelative
- Severe renal impairment / lupus nephritisOrgan ImpairmentRelative
- Pregnancy and lactationReproductiveRelative
Regulatory Status
- European UnionInvestigationalNot EMA approved. Clinical trials conducted in EU member states. Orphan designation explored.
- United StatesInvestigationalNot FDA approved. Studied under IND in Phase II/III trials for SLE (LUPUZOR, ARISE programs).
- United KingdomInvestigationalNot approved by MHRA. Status mirrors EU investigational classification.
Not approved by FDA, EMA, or other major regulatory agencies as of 2024. Studied under IND/clinical trial frameworks in the US and Europe. Orphan Drug Designation has been explored. Phase IIIARES trial results were mixed.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Forigerimod?
Forigerimod (P140 peptide, IPP-201101) is an investigational phosphopeptide being developed primarily for the treatment of systemic lupus erythematosus (SLE). It selectively targets overactivated immune cells without broadly suppressing the immune system. Phase II and Phase III clinical trials have been conducted, showing signals of efficacy in SLE patients, particularly in reducing disease activity scores.
What is Forigerimod used for?
Forigerimod is educationally associated with: Immune modulation without broad immunosuppression, Reduction of anti-dsDNA antibodies, Steroid-sparing effect, Reduction of SLE disease activity. Educational only — not medical advice.
How is Forigerimod administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Forigerimod?
Reported adverse effects include: Hypersensitivity reactions, Injection site reactions, Headache, Nausea, Fatigue. This list is not exhaustive — consult a qualified clinician.
Who should avoid Forigerimod?
Recorded contraindications: Hypersensitivity to forigerimod or excipients, Pregnancy, Active severe infection. Consult a qualified clinician before use.